Literature DB >> 18772733

[Impact of the French consensus guidelines on the management of colonic and rectal cancer: a population-based study].

F Borie1, M El Nasser, A Herrero, C Gras-Aygon, J-P Daures, B Tretarre.   

Abstract

AIM: To compare the management of colorectal cancer (CRC) before and after the French consensus conferences of rectal cancer (RC) in 1994 and colonic cancer (CC) in 1998.
METHODS: From 344 CCR incident cases in 1992 and 545 in 2000, patient characteristics, tumor data, and diagnostic and treatment modalities were collected to compare the management of CRC.
RESULTS: Post-operative mortality did not change significantly (4% in 1992 and 2.8% in 2000). No trends were observed in disease stage at diagnosis or rate of resection. For patients with CC (n=244 in 1992 and n=396 in 2000), the number of resection specimens with at least 12 lymph nodes increased from 11% in 1992 to 27% in 2000 (p<0.001). For CC with Dukes stage C and D, the use of chemotherapy increased significantly: for Dukes Stage C from 45% in 1992 to 55% in 2000; for Dukes Stage D from 37% in 1992 to 67% in 2000. For patients with RC (n=100 in 1992 and n=149 in 2000), no change in use of adjuvant radiotherapy was observed: 59% in 1992 versus 53.4% in 2000. Preoperative radiotherapy for RC was performed in 63% in 1992 and 75% in 2000 (p=0.7).
CONCLUSION: The consensus guidelines appear to have moderately influenced management practices. A better diffusion of guidelines to practitioners and a systematic evaluation of actual practices would be helpful to improve their impact.

Entities:  

Mesh:

Year:  2008        PMID: 18772733

Source DB:  PubMed          Journal:  J Chir (Paris)        ISSN: 0021-7697


  1 in total

1.  International preoperative rectal cancer management: staging, neoadjuvant treatment, and impact of multidisciplinary teams.

Authors:  Knut M Augestad; Rolv-Ole Lindsetmo; Jonah Stulberg; Harry Reynolds; Anthony Senagore; Brad Champagne; Alexander G Heriot; Fabien Leblanc; Conor P Delaney
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.